Skip to main content
World Today News
  • Home
  • News
  • World
  • Sport
  • Entertainment
  • Business
  • Health
  • Technology
Menu
  • Home
  • News
  • World
  • Sport
  • Entertainment
  • Business
  • Health
  • Technology

Improved Blood Test Matches Spinal Fluid Accuracy for Alzheimer’s, Study Finds

November 20, 2026 Health Desk Health

A blood test for Alzheimer’s disease matched the diagnostic accuracy of the standard spinal fluid test — at least 90% — in a study published November 18 in Nature Aging.

Key Clinical Takeaways:

  • An improved blood test measuring the protein p-tau217 detected Alzheimer’s disease pathology with 90–97% accuracy using regulator-approved cutoffs, matching cerebrospinal fluid testing.
  • The test is already approved in Europe, the United States and Japan, but is currently recommended only in specialist memory clinics.
  • Researchers are now working out how to bring the test into primary care, where diagnostic tools remain limited.

The study, led by Noëlle Warmenhoven of the Clinical Memory Research Unit at Lund University in Sweden, compared the plasma p-tau217 blood test against cerebrospinal fluid testing across three groups: a memory clinic cohort of 129 people, a primary care cohort of 220, and a research cohort of 165. PET imaging of the brain served as the reference standard throughout, confirming whether Alzheimer’s-related changes were actually present.

The result matters because cerebrospinal fluid testing — a lumbar puncture — has long been the standard in health care, and many clinicians have considered blood tests a close but inferior second.

“Previous studies have used cerebrospinal fluid tests as a reference standard. Based on those articles, there are many clinicians that therefore believe the new blood tests are good, but probably not as good as the cerebrospinal fluid tests we already use,” said Sebastian Palmqvist, associate professor and senior consultant neurologist at the Memory Clinic, Skåne University Hospital.

“However, the findings of this new study contradict this and suggest that a blood test is just as accurate as cerebrospinal fluid testing.”

The numbers behind the match

Using a single regulator-approved cutoff, plasma p-tau217 achieved accuracies of 83–91% and the p-tau217/Aβ42 ratio 83–92%, statistically comparable to the 88–90% range for cerebrospinal fluid tests across all three cohorts, according to the Nature Aging paper. With a two-cutoff approach in the clinical cohorts, plasma p-tau217’s accuracy rose to 90–97%, against 91% for the fluid test. All comparisons cleared the threshold for statistical equivalence.

Test and method Cohorts Accuracy
Plasma p-tau217, one cutoff All three cohorts 83–91%
Plasma p-tau217/Aβ42, one cutoff All three cohorts 83–92%
Cerebrospinal fluid biomarkers All three cohorts 88–90%
Plasma p-tau217, two cutoffs Clinical cohorts 90–97%
Cerebrospinal fluid biomarkers, two cutoffs Clinical cohorts 91%

Areas under the curve — a measure of overall diagnostic discrimination — ranged from 0.90 to 0.96 for the plasma biomarkers, the paper reported.

Why the cutoffs made the difference

The study’s design hinged on using predefined, regulator-approved cutoff values to classify results as positive, negative or inconclusive. Earlier studies frequently calculated their own cutoffs tuned to the study group at hand — values that do not carry over into clinical practice.

“For example, you could establish a cutoff that perfectly distinguishes between people with and without Alzheimer’s disease in Study A. But, if the same cutoff is then used in Study B, where the proportion of people without Alzheimer’s is significantly higher, this could lead to many false-positive results,” said Warmenhoven.

Regulator-approved cutoffs are built to be broadly applicable, and they are the values physicians will actually use at the point of care. That is what makes the equivalence finding clinically meaningful rather than a laboratory curiosity.

Who gains first

The blood test has already received authorization from the U.S. Food and Drug Administration and CE marking in Europe, and it is approved in Japan as well. For now, however, guidelines recommend it only in memory clinics and other specialist units — the settings that already have PET scanners and lumbar punctures available.

One in five women and one in 10 men develop Alzheimer’s disease during their lifetime, and primary care has long needed simpler, faster diagnostic methods. The blood test measures p-tau217, a biomarker specific to Alzheimer’s disease pathology. The U.S. version also measures amyloid-beta 42, the protein that accumulates into plaques in the Alzheimer’s brain — though the Lund researchers again found that the combination does not necessarily outperform p-tau217 alone.

The test can return an inconclusive result, in which case a PET scan or cerebrospinal fluid test remains necessary. Patients must also have cognitive symptoms for testing to be appropriate.

Primary care is the next test

Work is underway to determine what implementation in primary care might look like, Palmqvist said. A further step could follow if drug treatments prove effective at earlier stages.

“Further down the line, it may also become relevant to screen people with no memory problems at all, should drug treatments prove effective at that stage,” Palmqvist said.

For patients with cognitive symptoms, the practical change is that an accurate answer increasingly no longer requires a needle in the spine — a conversation to raise with a physician specializing in memory disorders or dementia care.

The study, “Comparing plasma p-tau217 and plasma p-tau217/Aβ42 with CSF biomarkers for assessing Alzheimer’s disease pathology,” appears in Nature Aging, published November 18.

The study was led from Lund University, one of Northern Europe’s oldest universities. Founded in 1666 on the site of a medieval studium generale next to Lund Cathedral, the university now has nine faculties and around 46,000 students.

Among researchers and alumni associated with it are five Nobel Prize winners and a Fields Medal winner, and its Clinical Memory Research Unit has produced a series of studies on blood-based biomarkers for Alzheimer’s disease.

Disclaimer: The information provided in this article is for educational and scientific communication purposes only and does not constitute medical advice. Always consult with a qualified healthcare provider regarding any medical condition, diagnosis, or treatment plan.

More on this story: Mayo Clinic Study: Blood Test Predicts Cognitive Impairment Risk 5-10 Years Ahead · Blood Tau Fragment Elevated in Advanced CTE, Studies Find

Share this:

  • Share on Facebook (Opens in new window) Facebook
  • Share on X (Opens in new window) X

Related reading

  • Velamentous Cord Insertion: Prenatal Diagnosis and Individualized Delivery Planning in a Primigravida with Cardiac Comorbidity
  • OLED Monitor Shipments Doubled YoY in Q3 2026 as MSI Overtakes Samsung for Second Place
  • Study Finds Malaria Antibody L9LS Blunts R21 Vaccine Response (time.news)

Related

Search:

World Today News

World Today News is your trusted source for global journalism — breaking headlines, in-depth analysis, and reporting from around the world.

Quick Links

  • Privacy Policy
  • About Us
  • Accessibility statement
  • California Privacy Notice (CCPA/CPRA)
  • Contact
  • Cookie Policy
  • Disclaimer
  • DMCA Policy
  • Do not sell my info
  • EDITORIAL TEAM
  • Terms & Conditions

Browse by Location

  • GB
  • NZ
  • US

Connect With Us

© 2026 World Today News. All rights reserved. Your trusted global news source directory.
For contact, advertising, copyright, issues email: [email protected]

Privacy Policy Terms of Service